ISRAEL ACQUISITIONS CORP-A (ISRL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ISRL • KYG496671010

12.4 USD
-0.1 (-0.8%)
Last: Dec 3, 2025, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ISRL. ISRL was compared to 0 industry peers in the Unkown industry. ISRL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ISRL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ISRL was profitable.
  • ISRL had a positive operating cash flow in the past year.
ISRL Yearly Net Income VS EBIT VS OCF VS FCFISRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M

1.2 Ratios

Industry RankSector Rank
ROA 13.8%
ROE 65.28%
ROIC N/A
ROA(3y)-1.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISRL Yearly ROA, ROE, ROICISRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • ISRL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISRL Yearly Profit, Operating, Gross MarginsISRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ISRL has less shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ISRL is higher compared to a year ago.
ISRL Yearly Shares OutstandingISRL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ISRL Yearly Total Debt VS Total AssetsISRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ISRL has an Altman-Z score of 5.17. This indicates that ISRL is financially healthy and has little risk of bankruptcy at the moment.
  • ISRL has a debt to FCF ratio of 1.02. This is a very positive value and a sign of high solvency as it would only need 1.02 years to pay back of all of its debts.
  • A Debt/Equity ratio of 0.76 indicates that ISRL is somewhat dependend on debt financing.
  • Although ISRL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF 1.02
Altman-Z 5.17
ROIC/WACCN/A
WACCN/A
ISRL Yearly LT Debt VS Equity VS FCFISRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that ISRL should not have too much problems paying its short term obligations.
  • ISRL has a Quick Ratio of 1.27. This is a normal value and indicates that ISRL is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
ISRL Yearly Current Assets VS Current LiabilitesISRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • ISRL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.78%.
EPS 1Y (TTM)-67.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ISRL is valuated quite expensively with a Price/Earnings ratio of 137.78.
  • When comparing the Price/Earnings ratio of ISRL to the average of the S&P500 Index (28.06), we can say ISRL is valued expensively.
Industry RankSector Rank
PE 137.78
Fwd PE N/A
ISRL Price Earnings VS Forward Price EarningsISRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 51.57
EV/EBITDA N/A
ISRL Per share dataISRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ISRL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ISRAEL ACQUISITIONS CORP-A

NASDAQ:ISRL (12/3/2025, 8:00:02 PM)

12.4

-0.1 (-0.8%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners46.19%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap78.74M
Revenue(TTM)N/A
Net Income(TTM)1.33M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 137.78
Fwd PE N/A
P/S N/A
P/FCF 51.57
P/OCF 51.57
P/B 38.52
P/tB 38.52
EV/EBITDA N/A
EPS(TTM)0.09
EY0.73%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.24
FCFY1.94%
OCF(TTM)0.24
OCFY1.94%
SpS0
BVpS0.32
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.81
Profitability
Industry RankSector Rank
ROA 13.8%
ROE 65.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF 1.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 114.42%
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 5.17
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.99%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1022.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1022.03%
OCF growth 3YN/A
OCF growth 5YN/A

ISRAEL ACQUISITIONS CORP-A / ISRL FAQ

What is the fundamental rating for ISRL stock?

ChartMill assigns a fundamental rating of 1 / 10 to ISRL.


Can you provide the valuation status for ISRAEL ACQUISITIONS CORP-A?

ChartMill assigns a valuation rating of 0 / 10 to ISRAEL ACQUISITIONS CORP-A (ISRL). This can be considered as Overvalued.


What is the profitability of ISRL stock?

ISRAEL ACQUISITIONS CORP-A (ISRL) has a profitability rating of 1 / 10.


What is the valuation of ISRAEL ACQUISITIONS CORP-A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ISRAEL ACQUISITIONS CORP-A (ISRL) is 137.78 and the Price/Book (PB) ratio is 38.52.


How financially healthy is ISRAEL ACQUISITIONS CORP-A?

The financial health rating of ISRAEL ACQUISITIONS CORP-A (ISRL) is 4 / 10.